Skip to main content
Erschienen in: Pituitary 2/2009

01.06.2009

Androgen deficiency: effects on body composition

verfasst von: Karen K. Miller

Erschienen in: Pituitary | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Published data on the effects of androgen deficiency and testosterone administration on body composition in men and women are reviewed. In experimental paradigms, androgen deprivation decreases lean body mass and increases fat mass in men, and physiologic replacement reverses these abnormalities. The anabolic effects of testosterone administration on muscle in men are well-established, and current understanding of the underlying mechanisms are discussed. Randomized, placebo-controlled studies have been performed to investigate the effects of testosterone administration on body composition in a number of male hypogonadal states, including HIV-associated weight loss, supraphysiologic glucocorticoid administration, aging and obesity, with variable outcomes, and the results are reviewed. There are few data investigating the effects of hypoandrogenemia or androgen replacement on body composition in women, in whom endogenous testosterone levels are a fraction of those in men. A recent randomized, placebo-controlled study of physiologic testosterone replacement therapy in women with profound hypoandrogenemia due to hypopituitarism demonstrated an increase in skeletal muscle mass but no change in body fat. Further research is needed to establish the effects of endogenous androgens on the regulation of body composition in women.
Literatur
1.
Zurück zum Zitat Brown-Sequard CE (1889) Note on the effects produced on man by subcutaneous injections of a liquid obtained from the testicles of animals. Lancet 2:105–107CrossRef Brown-Sequard CE (1889) Note on the effects produced on man by subcutaneous injections of a liquid obtained from the testicles of animals. Lancet 2:105–107CrossRef
2.
Zurück zum Zitat Cussons AJ, Bhagat CI, Fletcher SJ, Walsh JP (2002) Brown-Sequard revisited: a lesson from history on the placebo effect of androgen treatment. Med J Aust 177:678–679PubMed Cussons AJ, Bhagat CI, Fletcher SJ, Walsh JP (2002) Brown-Sequard revisited: a lesson from history on the placebo effect of androgen treatment. Med J Aust 177:678–679PubMed
4.
Zurück zum Zitat Butenandt A, Hanisch G (1935) Umwandlung des dehydro-androsterons in androsendiol und testosteron; ein weg zur darstellung des testosterons aus cholestrin. Hoppe Seylers Z Physiol Chem 237:89 Butenandt A, Hanisch G (1935) Umwandlung des dehydro-androsterons in androsendiol und testosteron; ein weg zur darstellung des testosterons aus cholestrin. Hoppe Seylers Z Physiol Chem 237:89
7.
Zurück zum Zitat Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A (1996) Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81:4358–4365. doi:10.1210/jc.81.12.4358 PubMedCrossRef Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A (1996) Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81:4358–4365. doi:10.​1210/​jc.​81.​12.​4358 PubMedCrossRef
8.
Zurück zum Zitat Katznelson L, Rosenthal D, Rosol M et al (1997) Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism. AJR Am J Roentgenol 170:423–427 Katznelson L, Rosenthal D, Rosol M et al (1997) Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism. AJR Am J Roentgenol 170:423–427
10.
11.
Zurück zum Zitat Galvao DA, Spry NA, Taaffe DR et al (2008) Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int [Epub ahead of print] Galvao DA, Spry NA, Taaffe DR et al (2008) Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int [Epub ahead of print]
12.
Zurück zum Zitat Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ (2003) Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 88:3167–3176. doi:10.1210/jc.2002-021827 PubMedCrossRef Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ (2003) Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 88:3167–3176. doi:10.​1210/​jc.​2002-021827 PubMedCrossRef
14.
Zurück zum Zitat Bhasin S, Storer TW, Asbel-Sethi N et al (1998) Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 83:3155–3162. doi:10.1210/jc.83.9.3155 PubMedCrossRef Bhasin S, Storer TW, Asbel-Sethi N et al (1998) Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 83:3155–3162. doi:10.​1210/​jc.​83.​9.​3155 PubMedCrossRef
16.
Zurück zum Zitat Grinspoon S, Corcoran C, Askari H et al (1998) Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 129:18–26PubMed Grinspoon S, Corcoran C, Askari H et al (1998) Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 129:18–26PubMed
17.
Zurück zum Zitat Grinspoon S, Corcoran C, Parlman K et al (2000) Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med 133:348–355PubMed Grinspoon S, Corcoran C, Parlman K et al (2000) Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med 133:348–355PubMed
19.
Zurück zum Zitat Dobs AS, Cofrancesco J, Nolten WE et al (1999) The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection. Am J Med 107:126–132. doi:10.1016/S0002-9343(99)00193-X PubMedCrossRef Dobs AS, Cofrancesco J, Nolten WE et al (1999) The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection. Am J Med 107:126–132. doi:10.​1016/​S0002-9343(99)00193-X PubMedCrossRef
21.
Zurück zum Zitat Storer TW, Woodhouse LJ, Sattler F et al (2005) A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment. J Clin Endocrinol Metab 90:4474–4482. doi:10.1210/jc.2005-0275 PubMedCrossRef Storer TW, Woodhouse LJ, Sattler F et al (2005) A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment. J Clin Endocrinol Metab 90:4474–4482. doi:10.​1210/​jc.​2005-0275 PubMedCrossRef
22.
Zurück zum Zitat Bhasin S, Calof OM, Storer TW et al (2006) Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2:146–159. doi:10.1038/ncpendmet0120 PubMedCrossRef Bhasin S, Calof OM, Storer TW et al (2006) Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2:146–159. doi:10.​1038/​ncpendmet0120 PubMedCrossRef
23.
Zurück zum Zitat Feldman HA, Longcope C, Derby CA et al (2002) Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87:589–598. doi:10.1210/jc.87.2.589 PubMedCrossRef Feldman HA, Longcope C, Derby CA et al (2002) Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87:589–598. doi:10.​1210/​jc.​87.​2.​589 PubMedCrossRef
24.
Zurück zum Zitat Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86:724–731. doi:10.1210/jc.86.2.724 PubMedCrossRef Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86:724–731. doi:10.​1210/​jc.​86.​2.​724 PubMedCrossRef
25.
Zurück zum Zitat Bhasin S, Woodhouse L, Casaburi R et al (2005) Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 90:678–688. doi:10.1210/jc.2004-1184 PubMedCrossRef Bhasin S, Woodhouse L, Casaburi R et al (2005) Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 90:678–688. doi:10.​1210/​jc.​2004-1184 PubMedCrossRef
26.
Zurück zum Zitat Page ST, Amory JK, Bowman FD et al (2005) Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90:1502–1510. doi:10.1210/jc.2004-1933 PubMedCrossRef Page ST, Amory JK, Bowman FD et al (2005) Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90:1502–1510. doi:10.​1210/​jc.​2004-1933 PubMedCrossRef
27.
28.
Zurück zum Zitat Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE (2003) Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci 58:618–625PubMed Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE (2003) Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci 58:618–625PubMed
30.
Zurück zum Zitat Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG (2001) Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 56:M266–M272PubMed Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG (2001) Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 56:M266–M272PubMed
32.
Zurück zum Zitat Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R (2003) AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 88:2673–2681. doi:10.1210/jc.2002-021058 PubMedCrossRef Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R (2003) AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 88:2673–2681. doi:10.​1210/​jc.​2002-021058 PubMedCrossRef
33.
Zurück zum Zitat Harman SM, Blackman MR (2003) The effects of growth hormone and sex steroid on lean body mass, fat mass, muscle strength, cardiovascular endurance and adverse events in healthy elderly women and men. Horm Res 60:121–124. doi:10.1159/000071236 PubMedCrossRef Harman SM, Blackman MR (2003) The effects of growth hormone and sex steroid on lean body mass, fat mass, muscle strength, cardiovascular endurance and adverse events in healthy elderly women and men. Horm Res 60:121–124. doi:10.​1159/​000071236 PubMedCrossRef
34.
Zurück zum Zitat Morley JE, Perry HM III, Kaiser FE et al (1993) Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 41:149–152PubMed Morley JE, Perry HM III, Kaiser FE et al (1993) Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 41:149–152PubMed
35.
Zurück zum Zitat Sih R, Morley JE, Kaiser FE, Perry HM III, Patrick P, Ross C (1997) Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 82:1661–1667. doi:10.1210/jc.82.6.1661 PubMedCrossRef Sih R, Morley JE, Kaiser FE, Perry HM III, Patrick P, Ross C (1997) Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 82:1661–1667. doi:10.​1210/​jc.​82.​6.​1661 PubMedCrossRef
36.
Zurück zum Zitat Calof OM, Singh AB, Lee ML et al (2005) Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 60:1451–1457PubMed Calof OM, Singh AB, Lee ML et al (2005) Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 60:1451–1457PubMed
37.
Zurück zum Zitat Barrett-Connor E, Khaw KT (1988) Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 78:539–545PubMed Barrett-Connor E, Khaw KT (1988) Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 78:539–545PubMed
38.
Zurück zum Zitat Seidell JC, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R (1990) Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 39:897–901. doi:10.1016/0026-0495(90) 90297-P PubMedCrossRef Seidell JC, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R (1990) Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 39:897–901. doi:10.​1016/​0026-0495(90) 90297-P PubMedCrossRef
39.
Zurück zum Zitat Zumoff B (1988) Hormonal abnormalities in obesity. Acta Med Scand Suppl 723:153–160PubMed Zumoff B (1988) Hormonal abnormalities in obesity. Acta Med Scand Suppl 723:153–160PubMed
40.
Zurück zum Zitat Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB (2006) Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91:843–850. doi:10.1210/jc.2005-1326 PubMedCrossRef Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB (2006) Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91:843–850. doi:10.​1210/​jc.​2005-1326 PubMedCrossRef
43.
Zurück zum Zitat Laaksonen DE, Niskanen L, Punnonen K et al (2005) The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 90:712–719. doi:10.1210/jc.2004-0970 PubMedCrossRef Laaksonen DE, Niskanen L, Punnonen K et al (2005) The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 90:712–719. doi:10.​1210/​jc.​2004-0970 PubMedCrossRef
44.
Zurück zum Zitat Marin P, Holmang S, Jonsson L et al (1992) The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 16:991–997PubMed Marin P, Holmang S, Jonsson L et al (1992) The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 16:991–997PubMed
47.
Zurück zum Zitat Khaw KT, Dowsett M, Folkerd E et al (2007) Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116:2694–2701. doi:10.1161/CIRCULATIONAHA.107.719005 PubMedCrossRef Khaw KT, Dowsett M, Folkerd E et al (2007) Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116:2694–2701. doi:10.​1161/​CIRCULATIONAHA.​107.​719005 PubMedCrossRef
51.
52.
Zurück zum Zitat Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H (2007) Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 92:405–413. doi:10.1210/jc.2006-1864 PubMedCrossRef Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H (2007) Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 92:405–413. doi:10.​1210/​jc.​2006-1864 PubMedCrossRef
54.
Zurück zum Zitat Judd HL, Judd GE, Lucas WE, Yen SS (1974) Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab 39:1020–1024PubMed Judd HL, Judd GE, Lucas WE, Yen SS (1974) Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab 39:1020–1024PubMed
55.
Zurück zum Zitat Judd HL, Lucas WE, Yen SS (1974) Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. Am J Obstet Gynecol 118:793–798PubMed Judd HL, Lucas WE, Yen SS (1974) Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. Am J Obstet Gynecol 118:793–798PubMed
56.
Zurück zum Zitat Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Muhlen D (2000) Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab 85:645–651. doi:10.1210/jc.85.2.645 PubMedCrossRef Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Muhlen D (2000) Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab 85:645–651. doi:10.​1210/​jc.​85.​2.​645 PubMedCrossRef
59.
Zurück zum Zitat Kim MH, Rosenfield RL, Dupon C (1976) The effects of dexamethasone on plasma free androgens during the normal menstrual cycle. Am J Obstet Gynecol 126:982–986PubMed Kim MH, Rosenfield RL, Dupon C (1976) The effects of dexamethasone on plasma free androgens during the normal menstrual cycle. Am J Obstet Gynecol 126:982–986PubMed
60.
Zurück zum Zitat Mathur RS, Landgrebe SC, Moody LO, Semmens JP, Williamson HO (1985) The effect of estrogen treatment on plasma concentrations of steroid hormones, gonadotropins, prolactin and sex hormone-binding globulin in post-menopausal women. Maturitas 7:129–133. doi:10.1016/0378-5122(85)90018-0 PubMedCrossRef Mathur RS, Landgrebe SC, Moody LO, Semmens JP, Williamson HO (1985) The effect of estrogen treatment on plasma concentrations of steroid hormones, gonadotropins, prolactin and sex hormone-binding globulin in post-menopausal women. Maturitas 7:129–133. doi:10.​1016/​0378-5122(85)90018-0 PubMedCrossRef
61.
Zurück zum Zitat Dor J, Bider D, Shulman A et al (2000) Effects of gonadotrophin-releasing hormone agonists on human ovarian steroid secretion in vivo and in vitro-results of a prospective, randomized in-vitro fertilization study. Hum Reprod 15:1225–1230. doi:10.1093/humrep/15.6.1225 PubMedCrossRef Dor J, Bider D, Shulman A et al (2000) Effects of gonadotrophin-releasing hormone agonists on human ovarian steroid secretion in vivo and in vitro-results of a prospective, randomized in-vitro fertilization study. Hum Reprod 15:1225–1230. doi:10.​1093/​humrep/​15.​6.​1225 PubMedCrossRef
62.
63.
Zurück zum Zitat Miller K, Corcoran C, Armstrong C et al (1998) Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. J Clin Endocrinol Metab 83:2717–2725. doi:10.1210/jc.83.8.2717 PubMedCrossRef Miller K, Corcoran C, Armstrong C et al (1998) Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. J Clin Endocrinol Metab 83:2717–2725. doi:10.​1210/​jc.​83.​8.​2717 PubMedCrossRef
64.
66.
67.
68.
Zurück zum Zitat Miller KK, Biller BM, Beauregard C et al (2006) Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 91:1683–1690. doi:10.1210/jc.2005-2596 PubMedCrossRef Miller KK, Biller BM, Beauregard C et al (2006) Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 91:1683–1690. doi:10.​1210/​jc.​2005-2596 PubMedCrossRef
69.
Zurück zum Zitat Miller KK, Biller BM, Schaub A et al (2007) Effects of testosterone therapy on cardiovascular risk markers in androgen-deficient women with hypopituitarism. J Clin Endocrinol Metab 92:2474–2479. doi:10.1210/jc.2007-0195 PubMedCrossRef Miller KK, Biller BM, Schaub A et al (2007) Effects of testosterone therapy on cardiovascular risk markers in androgen-deficient women with hypopituitarism. J Clin Endocrinol Metab 92:2474–2479. doi:10.​1210/​jc.​2007-0195 PubMedCrossRef
70.
Zurück zum Zitat Brodsky IG, Balagopal P, Nair KS (1996) Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab 81:3469–3475. doi:10.1210/jc.81.10.3469 PubMedCrossRef Brodsky IG, Balagopal P, Nair KS (1996) Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab 81:3469–3475. doi:10.​1210/​jc.​81.​10.​3469 PubMedCrossRef
71.
Zurück zum Zitat Urban RJ, Bodenburg YH, Gilkison C et al (1995) Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 269:E820–E826PubMed Urban RJ, Bodenburg YH, Gilkison C et al (1995) Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 269:E820–E826PubMed
72.
Zurück zum Zitat Sinha-Hikim I, Artaza J, Woodhouse L et al (2002) Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab 283:E154–E164PubMed Sinha-Hikim I, Artaza J, Woodhouse L et al (2002) Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab 283:E154–E164PubMed
73.
Zurück zum Zitat Singh AB, Hsia S, Alaupovic P et al (2002) The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 87:136–143. doi:10.1210/jc.87.1.136 PubMedCrossRef Singh AB, Hsia S, Alaupovic P et al (2002) The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 87:136–143. doi:10.​1210/​jc.​87.​1.​136 PubMedCrossRef
74.
Zurück zum Zitat Singh R, Artaza JN, Taylor WE et al (2006) Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 147:141–154. doi:10.1210/en.2004-1649 PubMedCrossRef Singh R, Artaza JN, Taylor WE et al (2006) Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 147:141–154. doi:10.​1210/​en.​2004-1649 PubMedCrossRef
75.
Zurück zum Zitat Bhasin S, Taylor WE, Singh R et al (2003) The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. J Gerontol A Biol Sci Med Sci 58:M1103–M1110PubMed Bhasin S, Taylor WE, Singh R et al (2003) The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. J Gerontol A Biol Sci Med Sci 58:M1103–M1110PubMed
76.
Zurück zum Zitat Bhasin S, Cunningham GR, Hayes FJ et al (2006) Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 91:1995–2010. doi:10.1210/jc.2005-2847 PubMedCrossRef Bhasin S, Cunningham GR, Hayes FJ et al (2006) Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 91:1995–2010. doi:10.​1210/​jc.​2005-2847 PubMedCrossRef
77.
Zurück zum Zitat Braunstein GD, Sundwall DA, Katz M et al (2005) Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 165:1582–1589. doi:10.1001/archinte.165.14.1582 PubMedCrossRef Braunstein GD, Sundwall DA, Katz M et al (2005) Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 165:1582–1589. doi:10.​1001/​archinte.​165.​14.​1582 PubMedCrossRef
78.
Zurück zum Zitat Buster JE, Kingsberg SA, Aguirre O et al (2005) Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 105:944–952PubMed Buster JE, Kingsberg SA, Aguirre O et al (2005) Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 105:944–952PubMed
79.
80.
Zurück zum Zitat Simon J, Braunstein G, Nachtigall L et al (2005) Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 90:5226–5233. doi:10.1210/jc.2004-1747 PubMedCrossRef Simon J, Braunstein G, Nachtigall L et al (2005) Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 90:5226–5233. doi:10.​1210/​jc.​2004-1747 PubMedCrossRef
Metadaten
Titel
Androgen deficiency: effects on body composition
verfasst von
Karen K. Miller
Publikationsdatum
01.06.2009
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 2/2009
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-008-0121-7

Weitere Artikel der Ausgabe 2/2009

Pituitary 2/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.